Abselion

📍 Cambridge, United Kingdom👥 25 employees💰 Last funded Feb 2021
Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules. We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Abselion?
Abselion has 1 investors on record on gritt.io.
When did Abselion last raise funding?
The most recent investment in Abselion recorded on gritt.io was in February 2021.
What industry is Abselion in?
Abselion operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Abselion based?
Abselion is headquartered in Cambridge, United Kingdom.